Paolo Casali

Personal Home Page

http://www.faculty.uci.edu/scripts/UCIFacultyProfiles/detailMBB.cfm?ID=4943

Articles in Scholarly Journals [Incomplete List]

  1. AID- and Ung-dependent generation of staggered double-strand DNA breaks in immunoglobulin class switch DNA recombination: A post-cleavage role for AID
    Molecular Immunology, 2008
  2. Nature and functions of autoantibodies
    Nature Clinical Practice Rheumatology, vol. 4, no. 9, Article ID ncprheum0895, 7 pages, 2008
  3. Molecular mechanisms of autoimmunity
    Autoimmunity, vol. 41, no. 2, pp. 123–132, 2008
  4. A role for DRAK2 in the germinal center reaction and the antibody response
    Autoimmunity, vol. 41, no. 5, pp. 341–352, 2008
  5. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
    British Journal of Cancer, vol. 96, no. 1, Article ID 6603542, 1 pages, 2007
  6. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005
    European Journal of Cancer, vol. 43, no. 6, pp. 974–978, 2007
  7. Crystal Structure of a Human Autoimmune Complex between IgM Rheumatoid Factor RF61 and IgG1 Fc Reveals a Novel Epitope and Evidence for Affinity Maturation
    Journal of Molecular Biology, vol. 368, no. 5, pp. 1321–1331, 2007
  8. Myxoid/round cell and pleomorphic liposarcomas
    Cancer, vol. 109, no. 12, pp. 2522–2531, 2007
  9. Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST
    Annals of Surgery, vol. 245, no. 3, pp. 341–346, 2007
  10. Chordoma
    Current Opinion in Oncology, vol. 19, no. 4, pp. 367–370, 2007
  11. c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors
    Clinical Cancer Research, vol. 13, no. 8, pp. 2369–2377, 2007
  12. Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution
    Annals of Surgical Oncology, vol. 14, no. 2, pp. 553–559, 2007
  13. Extremity Soft Tissue Sarcoma: Adding to the Prognostic Meaning of Local Failure
    Annals of Surgical Oncology, vol. 14, no. 5, pp. 1583–1590, 2007
  14. Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity
    Annals of Surgical Oncology, vol. 13, no. 1, pp. 110–117, 2006
  15. Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
    Annals of Surgical Oncology, vol. 13, no. 2, pp. 229–237, 2006
  16. Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas
    Clinical Cancer Research, vol. 12, no. 23, pp. 6920–6928, 2006
  17. PDGFRa, PDGFRß and KIT expression/activation in conventional chondrosarcoma
    The Journal of Pathology, vol. 208, no. 5, pp. 615–623, 2006
  18. Biased dA/dT somatic hypermutation as regulated by the heavy chain intronic iEµ enhancer and 3'Ea enhancers in human lymphoblastoid B cells
    Molecular Immunology, vol. 43, no. 11, pp. 1817–1826, 2006
  19. DNA repair in antibody somatic hypermutation
    Trends in Immunology, vol. 27, no. 7, pp. 313–321, 2006
  20. Malignant peripheral nerve sheath tumors
    Cancer, vol. 107, no. 5, pp. 1065–1074, 2006
  21. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    European Journal of Cancer, vol. 42, no. 8, pp. 1093–1103, 2006
  22. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
    European Journal of Cancer, vol. 42, no. 10, pp. 1484–1490, 2006
  23. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)
    European Journal of Cancer, vol. 42, no. 14, pp. 2277–2285, 2006
  24. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    The Lancet, 2006
  25. Reduced tetanus antibody titers in overweight children
    Autoimmunity, vol. 39, no. 2, pp. 137–141, 2006
  26. Reduced tetanus antibody titers in overweight children
    Autoimmunity, vol. 39, no. 4, pp. 349–349, 2006
  27. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
    Oncogene, vol. 25, no. 45, Article ID 1209639, 6 pages, 2006
  28. The translesion DNA polymerase ? plays a dominant role in immunoglobulin gene somatic hypermutation
    The EMBO Journal, vol. 24, no. 21, Article ID 7600833, 12 pages, 2005
  29. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
    European Journal of Cancer, vol. 41, no. 12, pp. 1751–1757, 2005
  30. Carney triad: case report and molecular analysis of gastric tumor
    Human Pathology, vol. 36, no. 1, pp. 112–116, 2005
  31. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system
    Cancer, vol. 103, no. 2, pp. 402–408, 2005
  32. Diffuse malignant mesothelioma of the peritoneum
    Cancer, vol. 104, no. 10, pp. 2181–2188, 2005
  33. DNA Lesions and Repair in Immunoglobulin Class Switch Recombination and Somatic Hypermutation
    Annals of the New York Academy of Sciences, vol. 1050, no. 1, pp. 146–162, 2005
  34. Adjuvant chemotherapy for soft tissue sarcoma
    Current Opinion in Oncology, vol. 17, no. 4, pp. 361–365, 2005
  35. Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
    Annals of Oncology, vol. 16, no. 4, pp. 566–578, 2005
  36. Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate
    Journal of Clinical Oncology, vol. 23, no. 30, pp. 7669–7675, 2005
  37. Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study
    Journal of Clinical Oncology, vol. 23, no. 24, pp. 5795–5804, 2005
  38. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial
    Endocrine Related Cancer, vol. 12, no. 3, pp. 657–666, 2005
  39. Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor   Tyrosine Kinase Receptors in Synovial Sarcoma
    Clinical Cancer Research, vol. 10, no. 3, pp. 938–943, 2004
  40. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
    Journal of Clinical Investigation, vol. 113, no. 4, pp. 646–646, 2004
  41. Retroperitoneal soft tissue sarcomas
    Cancer, vol. 100, no. 11, pp. 2448–2455, 2004
  42. Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution
    Cancer, vol. 101, no. 3, pp. 627–634, 2004
  43. Imatinib mesylate in chordoma
    Cancer, vol. 101, no. 9, pp. 2086–2097, 2004
  44. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    The Lancet, vol. 364, no. 9440, pp. 1127–1134, 2004
  45. Class switching and Myc translocation: how does DNA break?
    Nature Immunology, vol. 5, no. 11, Article ID ni1104-1101, 2 pages, 2004
  46. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
    Gastroenterology, vol. 127, no. 1, pp. 294–299, 2004
  47. Sacro-coccygeal chordoma: Diagnosis and treatment review
    Seminars in Colon and Rectal Surgery, vol. 15, no. 1, pp. 26–32, 2004
  48. The HoxC4 Homeodomain Protein Mediates Activation of the Immunoglobulin Heavy Chain 3' hs1,2 Enhancer in Human B Cells: RELEVANCE TO CLASS SWITCH DNA RECOMBINATION
    Journal of Biological Chemistry, vol. 279, no. 40, pp. 42258–42269, 2004
  49. Ongoing Immunoglobulin Class Switch DNA Recombination in Lupus B Cells: Analysis of Switch Regulatory Regions
    Autoimmunity, vol. 37, no. 6-7, pp. 431–443, 2004
  50. Selective Inhibition of Class Switching to IgG and IgE by Recruitment of the HoxC4 and Oct-1 Homeodomain Proteins and Ku70/Ku86 to Newly Identified ATTT cis-Elements
    Journal of Biological Chemistry, vol. 278, no. 25, pp. 23141–23150, 2003
  51. Journal of Clinical Immunology, vol. 23, no. 4, pp. 235–246, 2003
  52. Diversity and somatic hypermutation of the Ig VHDJH, V?J?, and V?J? Gene Segments in Lymphoma B cells: Relevance to the origin of the neoplastic B cell clone
    Human Immunology, vol. 64, no. 1, pp. 69–81, 2003
  53. AID-Dependent Generation of Resected Double-Strand DNA Breaks and Recruitment of Rad52/Rad51 in Somatic Hypermutation
    Immunity, vol. 18, no. 6, pp. 727–738, 2003
  54. Rhabdomyosarcoma in adults
    Cancer, vol. 98, no. 3, pp. 571–580, 2003
  55. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion
    Journal of Surgical Oncology, vol. 83, no. 3, pp. 147–153, 2003
  56. Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution
    Journal of Clinical Oncology, vol. 21, no. 7, pp. 1390–1397, 2003
  57. Gastrointestinal Stromal Tumors: Should They Be Treated with the Same Systemic Chemotherapy as Other Soft Tissue Sarcomas?
    Oncology, vol. 64, no. 2, pp. 186–188, 2003
  58. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
    Journal of Clinical Investigation, vol. 112, no. 11, pp. 1644–1654, 2003
  59. Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma
    Current Opinion in Orthopaedics, vol. 14, no. 6, pp. 419–428, 2003
  60. Chronic Lymphocytic Leukemia B Cells Can Undergo Somatic Hypermutation and Intraclonal Immunoglobulin VHDJH Gene Diversification
    Journal of Experimental Medicine, vol. 196, no. 5, pp. 629–639, 2002
  61. Somatic immunoglobulin hypermutation
    Current Opinion in Immunology, vol. 14, no. 2, pp. 235–240, 2002
  62. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL
    Nature Immunology, vol. 3, no. 9, Article ID ni829, 7 pages, 2002
  63. Inhibition of Fas-mediated Apoptosis by Antigen: Implications for Lymphomagenesis
    Autoimmunity, vol. 35, no. 4, pp. 283–289, 2002
  64. British Journal of Cancer, vol. 85, no. 10, pp. 1535–1539, 2001
  65. Nature Immunology, vol. 2, no. 2, pp. 150–156, 2001
  66. The Translesion DNA Polymerase ? Plays a Major Role in Ig and bcl-6 Somatic Hypermutation
    Immunity, vol. 14, no. 5, pp. 643–653, 2001
  67. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis
    Cancer, vol. 92, no. 5, pp. 1259–1264, 2001
  68. Cytokeratin Immunoreactivity in 41 Cases of ES/PNET Confirmed by Molecular Diagnostic Studies
    The American Journal of Surgical Pathology, vol. 25, no. 2, pp. 273–274, 2001
  69. Structure-function analysis of a lupus anti-DNA autoantibody: central role of the heavy chain complementarity-determining region 3 Arg in binding of double- and single-stranded DNA
    European Journal of Immunology, vol. 30, no. 7, pp. 2015–2026, 2000
  70. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered ß2-glycoprotein I
    Arthritis & Rheumatism, vol. 43, no. 1, pp. 140–150, 2000
  71. Promotion of Activated Human B Cell Apoptosis and Inhibition of Ig Production by Soluble CD95 Ligand: CD95-Based Downregulation of Ig Production Need Not Culminate in Activated B Cell Death
    Cellular Immunology, vol. 203, no. 1, pp. 1–11, 2000
  72. OUTCOME ASSESSMENT IN CANCER MANAGEMENT
    Surgical Clinics of North America, vol. 80, no. 2, pp. 471–486, 2000
  73. Ongoing hypermutation in the Ig V(D)J gene segments and c-myc proto-oncogene of an AIDS lymphoma segregates with neoplastic B cells at different sites: implications for clonal evolution
    Human Immunology, vol. 61, no. 12, pp. 1242–1253, 2000
  74. Annals of Oncology, vol. 11, no. 8, pp. 923–925, 2000
  75. Quality of Life Research, vol. 9, no. 2, pp. 151–159, 2000
  76. Annals of Oncology, vol. 10, no. 7, pp. 769–773, 1999
  77. Clonal evolution of B cells in transformation from low- to high-grade lymphoma
    European Journal of Immunology, vol. 29, no. 4, pp. 1253–1264, 1999
  78. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice
    Arthritis & Rheumatism, vol. 41, no. 6, pp. 1026–1039, 1998
  79. CD30 Is a CD40-Inducible Molecule that Negatively Regulates CD40-Mediated Immunoglobulin Class Switching in Non-Antigen-Selected Human B Cells
    Immunity, vol. 9, no. 2, pp. 247–256, 1998
  80. Annals of Oncology, vol. 8, no. 12, pp. 1207–1211, 1997
  81. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments
    Journal of Experimental Medicine, vol. 180, no. 3, pp. 885–895, 1994
  82. The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement
    Immunology Today, vol. 15, no. 8, pp. 367–373, 1994
  83. Generation of human monoclonal antibodies by transformation of lymphoblastoid B cells with ras oncogene
    Journal of Immunological Methods, vol. 160, no. 1, pp. 19–25, 1993
  84. Generation of human monoclonal antibody-producing cell lines by Epstein-Barr virus (EBV)-transformation of B lymphocytes and somatic cell hybridization techniques
    Journal of Tissue Culture Methods, vol. 14, no. 1, pp. 9–12, 1992
  85. Analysis of the Human CD5?CD45RAlow B-Cell Subset
    Annals of the New York Academy of Sciences, vol. 651, no. 1 CDS B Cells i, pp. 59–69, 1992
  86. Somatic Mutations in the VH Genes of High-Affinity Antibodies to Self and Foreign Antigens Produced by Human CD5+ and CD5? B Lymphocytes
    Annals of the New York Academy of Sciences, vol. 651, no. 1 CDS B Cells i, pp. 319–327, 1992
  87. Median sternotomy and multiple lung resections for metastatic sarcomas
    European Journal of Cardio-Thoracic Surgery, vol. 4, no. 9, pp. 477–481, 1990
  88. Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis
    Journal of Experimental Medicine, vol. 168, no. 6, pp. 1979–1992, 1988
  89. Viruses disrupt functions of human lymphocytes. Effects of measles virus and influenza virus on lymphocyte-mediated killing and antibody production
    Journal of Experimental Medicine, vol. 159, no. 5, pp. 1322–1337, 1984
  90. Natural killer cells activity in patients with multiple sclerosis given ? interferon
    Annals of Neurology, vol. 14, no. 3, pp. 333–338, 1983
  91. Mechanisms of killing of measles virus-infected cells by human lymphocytes: Interferon associated and unassociated cell-mediated cytotoxicity*1
    Cellular Immunology, vol. 70, no. 2, pp. 330–344, 1982
  92. In vitro generation of human cytotoxic lymphocytes by virus. Viral glycoproteins induce nonspecific cell-mediated cytotoxicity without release of interferon
    Journal of Experimental Medicine, vol. 154, no. 3, pp. 840–855, 1981
  93. COMPLEMENT IN ANGIO-$OElig;DEMA
    The Lancet, vol. 307, no. 7959, p. 587, 1976
  94. IMMUNE COMPLEXES IN MYASTHENIA GRAVIS
    The Lancet, vol. 308, no. 7981, p. 378, 1976
  95. Serum immunoconglutinins and complement in systemicLupus erythematosus
    Experientia, vol. 32, no. 12, pp. 1596–1597, 1976